Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alan Lewis Myers has a total of 144 co-authors. Here are the top co-authors by number of shared publications:

  • Yan-Ping Zhang

    Department of Pharmacy Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA

    5 shared publications
  • Hazem E. Hassan

    Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland, USA

    4 shared publications
  • Insong J. Lee

    Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland (H.E.H., A.L.M., I.J.L., C.W.M., D.W., H.W., N.D.E.); Bristol-Myers Squibb Co., Wallingford, Connecticut (M.W.S.); and Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Helwan University, Cairo, Egypt (H.E.H.)

    4 shared publications
  • Jitesh D. Kawedia

    University of Texas MD Anderson Cancer Center, Houston, TX, USA

    4 shared publications
  • Mark A Kramer

    Department of Pharmacy Research, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

    4 shared publications
  • Mark A. Kramer

    A Department of Pharmacy Research, Division of Pharmacy , The University of Texas M.D. Anderson Cancer Center , Houston , TX , USA

    4 shared publications

Latest Publications

  • Open Access

    The areca (betel) nut: clinical implications for dental practice in the United States

    by Tilomi Desai, Sayali Tungare, Simon Young, Nadarajah Vigneswaran, Ryan L. Quock, Alan L. Myers

  • Seizure Prophylaxis and its Impact on Busulfan Pharmacokinetics and Dosing in a Novel Timed Sequential Protocol: MD Anderson Experience

    by Jitesh D. Kawedia, Victoria W. Handy, Alan L. Myers, Alison M. Gulbis, Rohtesh Mehta, Richard E. Champlin, Elizabeth J. Shpall, Yago Nieto, Borje S. Andersson, Uday R. Popat


  • Open Access

    Comparison of Propofol Microbial Contamination Following Treatment With Drug Disposal Devices

    by Ransome van der Hoeven, Alan L. Myers

    Background: Pharmaceutical waste represents a major burden to the health care system and environment. Proper drug waste disposal devices are vitally needed, especially for propofol solutions that inherently carry a high risk of microbial contamination. Objectives: The aims of this study were to compare the capabilities of 2 drug disposal systems for decontamination of propofol solutions inoculated with medical pathogens and assess chemical degradation of propofol after treatment with Fenton reagents. Methods: Standard microbiological assays were used to assess survival and growth of Escherichia coli and Candida albicans inoculated into propofol solutions. Both a prototype instrument and a commercially marketed disposal device were tested for their ability to kill microbial growth. Furthermore, a propofol bioanalytical assay utilizing high-performance liquid chromatography (HPLC) was developed to measure propofol concentrations before and after treatment with a Fenton reagent cocktail (iron and hydrogen peroxide). Results: Propofol emulsion and diluted solutions lack antimicrobial properties and support the growth of microbes. The prototype instrument effectively killed E. coli and C. albicans inoculated into propofol solutions, while the commercial product did not kill or inhibit the growth of the microorganisms. Finally, propofol was chemically degraded to undetectable quantities (< 0.13 ppm) upon exposure to Fenton reagents in a prototype instrument. Conclusions: We show for the first time that propofol solutions inoculated with microbes are decontaminated upon exposure to Fenton reagents. Treatment with Fenton reagents also chemically destroys the propofol molecule. These results will support the development of novel drug disposal devices for real-time application in the pharmacy setting.

  • Open Access

    In vitro hydrolysis of areca nut xenobiotics in human liver

    by Vincenzo Paolillo, Mahendran Jayakumar, Colton Sheperd, Andrew Tran, Stephanie Hoang, Nhu Dao, Parag Jain, Alan L. Myers


  • Open Access

    Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy

    by Katherine M. Robinson, Seenae Eum, Zeruesenay Desta, Rachel F. Tyndale, Andrea Gaedigk, Richard C. Crist, Cyrine E. Haidar, Alan L. Myers, Caroline F. Samer, Andrew A. Somogyi, et al.

    Methadone is a mu (μ) opioid receptor agonist used clinically in adults and children to manage opioid use disorder, neonatal abstinence syndrome, and acute and chronic pain. It is typically marketed as a racemic mixture of R‐ and S‐enantiomers. R‐methadone has 30‐to 50‐fold higher analgesic potency than S‐methadone, and S‐methadone has a greater adverse effect (prolongation) on the cardiac QTc interval. Methadone undergoes stereoselective metabolism. CYP2B6 is the primary enzyme responsible for catalyzing the metabolism of both enantiomers to the inactive metabolites, S‐ and R‐2‐ethylidene‐1,5‐dimethyl‐3,3‐diphenylpyrrolidine (S‐ and R‐EDDP). Genetic variation in the CYP2B6 gene has been investigated in the context of implications for methadone pharmacokinetics, dose, and clinical outcomes. Most CYP2B6 variants result in diminished or loss of CYP2B6 enzyme activity, which can lead to higher plasma methadone concentrations (affecting S‐ more than R‐methadone). However, the data do not consistently indicate that CYP2B6‐based metabolic variability has a clinically significant effect on methadone dose, efficacy, or QTc prolongation. Expert analysis of the published literature does not support a change from standard methadone prescribing based on CYP2B6 genotype (updates at www.cpicpgx.org).


  • Provider-directed analgesia for dental pain

    by Alan L Myers, Arthur H Jeske

    Extraction of impacted molar teeth is a common procedure performed by oral surgeons and general dentists, with postoperative pain being a significant adverse event post-surgery. If mismanaged, pain...


  • Interactions of Betel Quid Constituents with Drug Disposition Pathways: An Overview

    by Alan L. Myers, Jasmine Canlas

    Global estimates indicate that over 600 million individuals worldwide consume the areca (betel) nut in some form. Nonetheless, its consumption is associated with a myriad of oral and systemic ailments, such as precancerous oral lesions, oropharyngeal cancers, liver toxicity and hepatic carcinoma, cardiovascular distress, and addiction. Users commonly chew slivers of areca nut in a complex consumable preparation called betel quid (BQ). Consequently, the user is exposed to a wide array of chemicals with diverse pharmacokinetic behavior in the body. However, a comprehensive understanding of the metabolic pathways significant to BQ chemicals is lacking. Henceforth, we performed a literature search to identify prominent BQ constituents and examine each chemical's interplay with drug disposition proteins. In total, we uncovered over 20 major chemicals (e.g., arecoline, nicotine, menthol, quercetin, tannic acid) present in the BQ mixture that were substrates, inhibitors, and/or inducers of various phase I (e.g., CYP, FMO, hydrolases) and phase II (e.g., GST, UGT, SULT) drug metabolizing enzymes, along with several transporters (e.g., P-gp, BCRP, MRP). Altogether, over 80 potential interactivities were found. Utilizing this new information, we generated theoretical predictions of drug interactions precipitated by BQ consumption. Data suggests that BQ consumers are at risk for drug interactions (and possible adverse effects) when co-ingesting other substances (multiple therapeutic classes) with overlapping elimination mechanisms. Until now, prediction about interactions is not widely known among BQ consumers and their clinicians. Further research is necessary based on our speculations to elucidate the biological ramifications of specific BQ-induced interactions and to take measures that improve the health of BQ consumers.


  • Metabolism of the areca alkaloids – toxic and psychoactive constituents of the areca (betel) nut

    by Alan L. Myers

    Areca nut (AN) is consumed by millions of people for its therapeutic and psychoactive effects, making it one of the most widely self-administered psychoactive substances in the world. Even so, AN use/abuse is associated with myriad oral and systemic side effects, affecting most organ systems in the body. Alkaloids abundant in the nut (e.g., arecoline, arecaidine, guvacoline, guvacine), collectively called the areca alkaloids, are presumably responsible for the major pharmacological effects experienced by users, with arecoline being the most abundant alkaloid with notable toxicological properties. However, the mechanisms of arecoline and other areca alkaloid elimination in humans remains poorly documented. Therefore, the purpose of this review is to provide an in-depth review of areca alkaloid pharmacokinetics in biological systems, and discuss mechanisms of metabolism by presenting information found in the literature. Also, the toxicological relevance of the known and purported metabolic steps will be reviewed. In brief, several areca alkaloids contain a labile methyl ester group and are susceptible to hydrolysis, although the human esterase responsible remains presumptive. Other notable mechanisms include N-oxidation, glutathionylation, nitrosamine conversion and carbon–carbon double-bond reduction. These metabolic conversions result in toxic and sometimes less-toxic derivatives. Arecoline and arecaidine undergo extensive metabolism while far less is known about guvacine and guvacoline. Metabolism information may help predict drug interactions with human pharmaceuticals with overlapping elimination pathways. Altogether, this review provides a first-of-its-kind comprehensive analysis of AN alkaloid metabolism, adds perspective on new mechanisms of metabolism, and highlights the need for future metabolism work in the field.